260 related articles for article (PubMed ID: 30504402)
21. Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC.
Franken LC; Vuijk FA; Soer EC; Roos E; Erdmann JI; Hooijer GKJ; Vahrmeijer AL; Gambhir SS; van Gulik TM; Sarasqueta AF; Verheij J; Swijnenburg RJ
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):628-634. PubMed ID: 33069505
[TBL] [Abstract][Full Text] [Related]
22. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
23. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.
Röcken C; Licht J; Roessner A; Carl-McGrath S
J Clin Pathol; 2005 Oct; 58(10):1069-75. PubMed ID: 16189153
[TBL] [Abstract][Full Text] [Related]
24. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
Hunt JP; Varnholt H
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
[No Abstract] [Full Text] [Related]
25. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.
Lamps LW; Folpe AL
Adv Anat Pathol; 2003 Jan; 10(1):39-43. PubMed ID: 12502967
[TBL] [Abstract][Full Text] [Related]
26. Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma.
Görög D; Regöly-Mérei J; Paku S; Kopper L; Nagy P
World J Gastroenterol; 2005 Aug; 11(32):5015-8. PubMed ID: 16124056
[TBL] [Abstract][Full Text] [Related]
27. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
28. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
[TBL] [Abstract][Full Text] [Related]
29. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.
Fu X; Tan L; Liu S; Li H; Chen L; Qin J; Wu M; Wang H
J Cancer Res Clin Oncol; 2004 Sep; 130(9):514-20. PubMed ID: 15221469
[TBL] [Abstract][Full Text] [Related]
30. Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
Chen L; Zeng F; Yao L; Fang T; Liao M; Long J; Xiao L; Deng G
Cancer Med; 2020 Feb; 9(4):1451-1461. PubMed ID: 31903730
[TBL] [Abstract][Full Text] [Related]
31. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
[TBL] [Abstract][Full Text] [Related]
32. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
Sasaki M; Nakanuma Y; Ho SB; Kim YS
Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202
[TBL] [Abstract][Full Text] [Related]
33. Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
Zhang X; Huang WJ; Zhang ML; Wang W; Niu Y; Wang RT; Liu ZY
BMC Gastroenterol; 2022 Jun; 22(1):288. PubMed ID: 35668355
[TBL] [Abstract][Full Text] [Related]
34. [Combined hepatocellular-cholangiocarcinoma].
Jeen YM; Jin SY
Korean J Hepatol; 2007 Dec; 13(4):571-5. PubMed ID: 18159156
[No Abstract] [Full Text] [Related]
35. The utility of villin and mammaglobin in the differential diagnosis between intrahepatic cholangiocarcinoma and breast cancer.
Yang Z
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):19-25. PubMed ID: 25153498
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
Radwan NA; Ahmed NS
Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
38. [A comparative study of intrahepatic cholangiocarcinoma and hepatocellular carcinoma with reference to clinical features and prognosis].
Hu JY; Zhou HB; Liu WD; Zhang J; Hu HP; Liu J
Zhonghua Gan Zang Bing Za Zhi; 2019 Jul; 27(7):511-515. PubMed ID: 31357776
[No Abstract] [Full Text] [Related]
39. [CT and MR imaging differences between intrahepatic cholangiocarcinoma and hepatocellular carcinoma with invasions to billary tracts].
Yang NJ; Song B; Wu B; Xu J; Zhao LM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):525-8. PubMed ID: 19627020
[TBL] [Abstract][Full Text] [Related]
40. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
